Leiden University Scholarly Publications

Persistent URL of this record https://hdl.handle.net/1887/3185054

In Collections

This item can be found in the following collections:

Baron, F.; Efficace, F.; Cannella, L.; Muus, P.; Trisolini, S.; Halkes, C.J.M.; ... ; Suciu, S. (2020)

Impact of the type of anthracycline and of stem cell transplantation in younger patients with acute myeloid leukemia: long-term follow up of a phase III study

Article / Letter to editor
We provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m(2)), mitoxantrone (MXR, 12 mg/m(2)), or idarubicin (IDA, 10 mg/m(2)) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P = .38). In young patients, 15-45 years old, no treatment...Show moreWe provide a long-term evaluation of patients enrolled in the EORTC/GIMEMA AML-10 trial which included a total of 2157 patients, 15-60 years old, randomized to receive either daunorubicin (DNR, 50 mg/m(2)), mitoxantrone (MXR, 12 mg/m(2)), or idarubicin (IDA, 10 mg/m(2)) in addition to standard-dose cytarabine and etoposide for induction chemotherapy and intermediate dose cytarabine for consolidation. Younger patients who reached complete remission with complete (CR) or incomplete (CRi) recovery were then scheduled to receive an allogeneic hematopoietic stem cell transplantation (HSCT). That was if they had a HLA-identical sibling donor; in all other cases, an autologous HSCT had to be administered. At an 11-year median follow-up, the 5-year, 10-year and 15-year overall survival (OS) rates were 33.2%, 30.1% and 28.0%, respectively. No significant difference between the three randomized groups regarding OS was observed (P = .38). In young patients, 15-45 years old, no treatment difference (P = .89) regarding OS was observed, while in patients 46-60 years old, MXR and IDA groups had a trend for a longer OS as compared to the DNR group (P = .029). Among younger patients without a favorable MRC cytogenetic risk subgroup who achieved a CR/CRi after induction chemotherapy, those with a HLA-identical sibling donor had higher 10-year and 15-year OS rates than those without. In older patients who reached CR/CRi, the long-term outcomes of those with or without a donor was similar. In conclusion, long-term outcomes of the study confirmed similar OS in the three randomized groups in the whole cohort of patients.Show less
All authors
Baron, F.; Efficace, F.; Cannella, L.; Muus, P.; Trisolini, S.; Halkes, C.J.M.; Fazi, P.; Vignetti, M.; Marie, J.P.; Chiusolo, P.; Velden, W. van der; Sala, E. la; Vitolo, U.; Thomas, X.; Lefrere, F.; Raimondo, F. di; Bourhis, J.H.; Specchia, G.; Guimaraes, J.E.; Allione, B.; Vrhovac, R.; Ferrara, F.; Stevens-Kroef, M.; Meert, L.; Witte, T. de; Willemze, R.; Amadori, S.; Suciu, S.
Date
2020-04-17
Journal
American Journal of Hematology
Volume
95
Issue
7
Pages
749 - 758
DOI
doi:10.1002/ajh.25795
Link
https://onlinelibrary.wiley.com/doi/10.1002/ajh.25795